HLA-Cw*0602等位基因在银屑病患者中的表达及对不同种类生物制剂治疗中的影响Meta分析

Expression of HLA-Cw*0602 allele in patients with psoriasis and its effect on biological therapy:a Meta analysis

目的 分析HLA-Cw*0602等位基因在银屑病患者中的表达和对不同种类生物制剂治疗银屑病疗效的影响。方法 计算机检索2011年1月—2021年12月万方医学数据库、中国学术期刊网全文数据库、博库科技数据库、Embase、PubMed、 Cochrane等数据库中关于HLA-Cw*0602等位基因在银屑病患者中的表达和对不同种类生物制剂治疗银屑病疗效的影响文献,筛选提取资料和评价质量后采用Stata 14.0软件进行Meta分析。结果 共纳入符合标准的文献10篇,银屑病患者中HLA-Cw*0602等位基因阳性平均表达率为43%;HLA-Cw*0602阳性患者在使用IL-12/23p40抑制剂类生物制剂治疗后12/16周PASI75、12/16周PASI90、24/28周PASI75、24/28周PASI90的比例均高于HLA-Cw*0602阴性者(P<0.05)。结论 HLA-Cw*0602等位基因在不同地区的阳性率差距较大,携带HLACw*0602等位基因的银屑病患者使用IL-12/23p40抑制剂类生物制剂治疗可获得更好的生物制剂治疗效果。

Objective To analyze the expression ofHLA-Cw*0602 allele in patients with psoriasis and its effect on the efficacy of different biological agents in the treatment of psoriasis.Methods From January 2011 to December 2021,we searched CNKI,Wanfang database,EMBASE,PubMed,Cochrane and other databases for literatures about the expression ofHLACw*0602 allele in patients with psoriasis and its effect on the efficacy of different biological agents in the treatment of psoriasis,screened the literatures,extracted the data and evaluated the quality,and then used Stata 14.0 software for meta-analysis.Results A total of 10 literatures were included.The results showed that the average positive expression rate ofHLA-Cw*0602 allele in patients with psoriasis was 43%;After treatment with IL-12/23p40 inhibitor biological agents,the proportion of12/16 weeks PASI75,12/16 weeks PASI90,24/28 weeks PASI75,24/28 week PASI90 inHLA-Cw* 0602 positive patients were higher than those inHLA-Cw* 0602 negative patients(P< 0.05).Conclusion The positive rates ofHLA-Cw*0602 allele in different regions are quite different,and patients with psoriasis carryingHLA-Cw*0602 allele can get better therapeutic effect by using IL-12/23p40 inhibitor biological agents.